A new cell and gene therapy point of care treatment facility at Johns Hopkins University, expected to open in 2023, has boosted both the state’s importance, as well as Baltimore’s importance as a lynchpin in the cell and gene therapy industry.
Orgenesis and Johns Hopkins Partner to Boost Cell and Gene Therapy Manufacturing for Point of Care Treatment in Baltimore
